CELLphenomics and Charles River Announce Agreement, Expanding 3D In Vitro Services for Cancer Therapy Drug Screening
CELLphenomics and Charles River Laboratories International, Inc. (NYSE: CRL) announced an agreement, that provides Charl…
CELLphenomics and Charles River Laboratories International, Inc. (NYSE: CRL) announced an agreement, that provides Charl…
Exascend, a service-oriented provider of innovative storage and memory solutions, is proud to announce that its PI4 seri…
faCellitate expands its product range with the launch of three new BIOFLOAT™ -coated flat-bottom microplates; a 96-well…
SPECTRO Analytical Instruments today announced the latest generation of SPECTRO XEPOS spectrometers, representing anothe…
The Global 3D Cell Culture Market is expected to witness a double-digit growth rate by 2027. Some of the key factors dri…
Responding to high demand, ibidi has expanded their popular µ-Plate 96 Well to include both square and round wells. By a…
First Tin PLC, ("First Tin" or "the Company" - https://www.commodity-tv.com/...) a tin development company with advance…
Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Bayer AG, today anno…
The research project, named IMPACT - Cardiogenomics meets Artificial Intelligence: a step forward in arrhythmogenic card…
KYAN Technologies, a vanguard combinatory drug development solutions provider, is thrilled to announce a strategic partn…